Amicus Therapeutics opened the $25 million Global Research and Gene Therapy Center of Excellence in March of 2020 in Philadelphia. Accommodating up to 200 employees, the 75,000-sf project provides collaborative labs and offices to support the discovery and development of new therapies for rare metabolic diseases.
Audentes Therapeutics is planning to construct a $109 million gene therapy manufacturing facility in Sanford, N.C. The 135,000-sf project will support the production of genetic medicines based on adeno-associated virus vectors for the treatment of rare neuromuscular diseases. The center is expected to be operational by 2021. Audentes Therapeutics is a subsidiary of Astellas Pharma.
Athenex is constructing a $210 million pharmaceutical plant in Dunkirk, N.Y. Supporting the production of advanced cancer therapies, the 409,000-sf complex will provide research, office, manufacturing, and warehouse space. General contractor Exyte broke ground on the facility in May of 2018, and commercial operations will commence at the site in early 2022. The project is part of a strategic infrastructure development plan to enable Athenex to offer vertically integrated oncology services from discovery through marketing.
The University of Iowa opened the $96.3 million College of Pharmacy in January of 2020 in Iowa City. Designed by OPN Architects and The S/L/A/M Collaborative, the 228,371-sf facility features a pharmacy practice simulation center, 23 instructional spaces, 16 flexible research labs, collaboration areas, and a 128-seat lecture hall for team-based learning. The structure stands six stories above grade, with a lower level housing two sterile production lines, a warehouse, and a vault to store controlled substances.
Merck KGaA broke ground in early 2020 on the $275 Biotech Development Center in Corsier-sur-Vevey, Switzerland. Constructed adjacent to the company's existing commercial manufacturing campus, the 169,000-sf project will provide advanced research, development, and production facilities to support the creation of innovative biological compounds for clinical studies.
Eli Lilly and Company opened the 11,500-sf Lilly Life Sciences Studio in San Diego in January of 2020. Part of a $90 million investment to expand the company's research footprint, the laboratory leverages a robotic cloud platform created by Strateos to enable other drug discovery companies and investigators to access the remote-controlled facility.
Eli Lilly & Company is planning to build a $474 million pharmaceutical manufacturing center in Durham, N.C. Located in Research Triangle Park, the next-generation facility will produce injectable therapeutics and delivery devices for conditions such as Type 2 diabetes. Accommodating over 450 new employees, the project will provide integrated manufacturing, engineering, and warehouse areas. Operations will commence at the site in 2023.
Foghorn Therapeutics broke ground in January of 2020 on its 60,000-sf headquarters in Cambridge, Mass. Located in Kendall Square, the facility will provide chemistry and biology labs, open offices, conference rooms, huddle rooms, and an employee café. Foghorn will occupy over three floors in the building, which is owned by Alexandria Real Estate Equities and managed by CBRE.
The National Institutes of Health is planning to build a dementia research center in Bethesda, Md. The 24,000-sf facility will provide labs, open collaboration spaces, conference rooms, and offices to support the discovery of new diagnostic tools and treatments for Alzheimer's disease and related conditions. The single-story structure will be delivered in less than two years using modular construction technologies. The cost of the project has yet to be determined, with estimates ranging from $25 to $100 million.
St. Jude's Children's Research Hospital is constructing the $13.4 million Shared Resource Center in Memphis, Tenn. Accommodating 60 employees, the project will provide core laboratories and instrumentation suites to accelerate the discovery of new treatments for pediatric cancer and other diseases. Created inside an existing 300,000-sf warehouse, the 100,000-sf center will house:
Amgen has leased a 240,000-sf research facility located on the Gateway of Pacific campus in South San Francisco, Calif. Amgen will occupy the entire north tower, which is being constructed by BioMed Realty as part of the second phase of development at the site. Featuring modular wet and molecular labs designed for optimal energy efficiency, the facility will accommodate Amgen's research programs in oncology, inflammation, and cardiometabolic diseases.
The new 100,000-sf AstraZeneca site in South San Francisco, located in the Cove at Oyster Point complex, is the company’s first facility where open offices and labs are seamlessly integrated with each other to promote increased mobility and interaction among the researchers. Housing around 400 employees, the building brings together staff from AstraZeneca’s Technology Innovation & Delivery Excellence (TIDE) unit, as well as subsidiaries MedImmune, Acerta Pharma, and Pearl Therapeutics into one state-of-the-art facility at the center of the Bay Area’s vibrant biotech and technology sector.
HALIX opened a 72,000-sf biopharmaceutical development and manufacturing center in November of 2019 at Leiden Bio Science Park in the Netherlands. The five-story structure provides BSL-2 cleanrooms with unidirectional process flows that can easily be upgraded to BSL-3 as needed. A manufacturing line with a 250-liter bioreactor capacity supports the production of viral vaccines and viral vectors, while a separate protein manufacturing area accommodates single-use bioreactors with a capacity of up to 1,000 liters.
The University of Hawaii at Hilo dedicated the $31 million Daniel K. Inouye College of Pharmacy in December of 2019. Designed by SmithGroup and WCIT Architecture, the 45,000-sf facility offers technology-rich environments for applied learning including collaborative classrooms, teaching labs, seminar rooms, and a simulated pharmacy. The three-story structure includes research labs for pharmaceutical discovery as well as a medication therapy management suite, consultation rooms, and a resource center.
Thermo Fisher Scientific opened a $90 million viral vector facility in December of 2019 in Lexington, Mass. Featuring specialized GMP laboratories, the 50,000-sf project will accommodate the development, testing, and manufacture of viral vectors for the creation of gene and cell therapies. The center will act as a CDMO (contract development and manufacturing organization) site and will offer services including from drug development through clinical trials and commercial production.
